Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

BCYC - Bicycle Therapeutics plc So'nggi... | Finranks

Home

BCYC

B

Bicycle Therapeutics plc (BCYC)

NMS – Real vaqt narxi. Valyuta: USD

4.31

-0.19 (-4.22%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

4.33

+0.02 (0.46%)

Bozordan keyin: Mar 27, 2026, 7:29 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Videolar

No Data

There is no data to display

Press-relizlar

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations of five abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego. Presentation Details: Title: Preclinical assessment of BT552.

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent corporate updates. “We have successfully completed the dose selection portion of the Duravelo-2 trial and received regulatory alignment that the 6mg.

Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline

Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced leadership transitions for its next phase of innovation. Travis Thompson, who began at Bicycle in April 2018 and most recently served as Bicycle's senior vice president and chief accounting officer and previously spent his career at EY in its life.

Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today highlights 2025 accomplishments and strategic priorities for 2026. "In 2025, we remained steadfast in our goal of helping patients live longer and live well, making meaningful advancements to our pipeline and strengthening the operational capabilities that s.